Apogee Therapeutics IncNASDAQ:APGE
- LAST PRICE58.2900
- TODAY'S CHANGE (%)1.9900 (3.5346%)
- Bid / Lots54.4700/ 1
- Ask / Lots59.9600/ 1
- Open / Previous Close56.4800 / 56.3000
- Day Range
- 52 Week Range
- Volume326,031
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | APGE |
|---|---|---|
| 09:32 ET | 1507 | 55.53 |
| 09:37 ET | 733 | 56 |
| 09:39 ET | 419 | 56.62 |
| 09:42 ET | 300 | 56.63 |
| 09:48 ET | 1577 | 56.38 |
| 09:50 ET | 200 | 56.375 |
| 09:53 ET | 651 | 56.75 |
| 09:55 ET | 342 | 56.84 |
| 09:57 ET | 13416 | 57 |
| 10:00 ET | 300 | 57.14 |
| 10:02 ET | 3850 | 57 |
| 10:04 ET | 1794 | 57.3823 |
| 10:06 ET | 19200 | 57.39 |
| 10:08 ET | 1804 | 57 |
| 10:09 ET | 700 | 56.73 |
| 10:11 ET | 1100 | 56.65 |
| 10:13 ET | 945 | 56.58 |
| 10:18 ET | 400 | 56.9899 |
| 10:22 ET | 900 | 56.17 |
| 10:24 ET | 1900 | 56.51 |
| 10:26 ET | 2972 | 56.95 |
| 10:29 ET | 5056 | 56.5 |
| 10:31 ET | 427 | 56.425 |
| 10:33 ET | 100 | 56.425 |
| 10:36 ET | 100 | 56.425 |
| 10:38 ET | 349 | 56.425 |
| 10:42 ET | 100 | 56.44 |
| 10:45 ET | 263 | 56.68 |
| 10:47 ET | 245 | 56.515 |
| 10:49 ET | 100 | 56.425 |
| 10:51 ET | 100 | 56.74 |
| 10:54 ET | 1407 | 56.5 |
| 10:56 ET | 100 | 56.62 |
| 11:00 ET | 200 | 56.62 |
| 11:02 ET | 200 | 56.73 |
| 11:03 ET | 200 | 56.66 |
| 11:05 ET | 200 | 56.66 |
| 11:09 ET | 100 | 56.665 |
| 11:12 ET | 400 | 56.66 |
| 11:14 ET | 2200 | 56.86 |
| 11:18 ET | 900 | 57.13 |
| 11:20 ET | 100 | 57.33 |
| 11:21 ET | 1760 | 57.115 |
| 11:23 ET | 100 | 57.17 |
| 11:25 ET | 1011 | 57.24 |
| 11:27 ET | 100 | 57.04 |
| 11:32 ET | 100 | 57.22 |
| 11:34 ET | 200 | 57.16 |
| 11:36 ET | 7781 | 57.31 |
| 11:38 ET | 2500 | 57.29 |
| 11:41 ET | 300 | 57.2875 |
| 11:43 ET | 100 | 57.16 |
| 11:45 ET | 300 | 57.105 |
| 11:48 ET | 368 | 57.16 |
| 11:50 ET | 200 | 57.12 |
| 11:56 ET | 100 | 57.21 |
| 11:57 ET | 100 | 57.21 |
| 11:59 ET | 200 | 57.255 |
| 12:01 ET | 700 | 57.205 |
| 12:03 ET | 100 | 57.115 |
| 12:06 ET | 100 | 57.195 |
| 12:15 ET | 302 | 57.32 |
| 12:17 ET | 700 | 57.35 |
| 12:19 ET | 200 | 57.35 |
| 12:28 ET | 6990 | 57.225 |
| 12:30 ET | 900 | 57.43 |
| 12:35 ET | 2200 | 57.55 |
| 12:39 ET | 700 | 57.33 |
| 12:46 ET | 500 | 57.25 |
| 12:48 ET | 700 | 57.34 |
| 12:55 ET | 400 | 57.49 |
| 12:57 ET | 200 | 57.23 |
| 01:00 ET | 300 | 57.355 |
| 01:02 ET | 100 | 57.25 |
| 01:04 ET | 400 | 57.335 |
| 01:06 ET | 700 | 57.355 |
| 01:09 ET | 1000 | 57.28 |
| 01:13 ET | 100 | 57.1 |
| 01:18 ET | 300 | 57.01 |
| 01:27 ET | 500 | 57.06 |
| 01:29 ET | 1363 | 57.1 |
| 01:31 ET | 900 | 57.085 |
| 01:33 ET | 1154 | 57.28 |
| 01:36 ET | 600 | 57.37 |
| 01:40 ET | 100 | 57.235 |
| 01:45 ET | 1347 | 57.315 |
| 01:49 ET | 300 | 57.13 |
| 01:54 ET | 100 | 57.235 |
| 02:03 ET | 1201 | 57.34 |
| 02:14 ET | 100 | 57.38 |
| 02:21 ET | 200 | 57.29 |
| 02:25 ET | 300 | 57.305 |
| 02:27 ET | 100 | 57.22 |
| 02:32 ET | 200 | 57.25 |
| 02:38 ET | 508 | 57.2 |
| 02:39 ET | 100 | 57.26 |
| 02:41 ET | 400 | 57.26 |
| 02:43 ET | 1000 | 57.56 |
| 02:50 ET | 100 | 57.575 |
| 02:52 ET | 10500 | 57.705 |
| 02:54 ET | 5500 | 57.915 |
| 02:56 ET | 11600 | 57.915 |
| 02:57 ET | 3900 | 57.63 |
| 02:59 ET | 300 | 57.46 |
| 03:01 ET | 2323 | 57.26 |
| 03:03 ET | 900 | 57.5 |
| 03:08 ET | 3787 | 57.645 |
| 03:10 ET | 1400 | 57.6 |
| 03:12 ET | 1300 | 57.68 |
| 03:14 ET | 800 | 57.58 |
| 03:15 ET | 200 | 57.525 |
| 03:17 ET | 800 | 57.665 |
| 03:19 ET | 1100 | 57.545 |
| 03:21 ET | 100 | 57.59 |
| 03:24 ET | 100 | 57.58 |
| 03:28 ET | 9950 | 57.855 |
| 03:32 ET | 300 | 57.705 |
| 03:33 ET | 100 | 57.805 |
| 03:35 ET | 100 | 57.845 |
| 03:37 ET | 17008 | 57.865 |
| 03:39 ET | 5876 | 57.88 |
| 03:42 ET | 1298 | 57.8003 |
| 03:44 ET | 4053 | 57.98 |
| 03:46 ET | 400 | 58 |
| 03:48 ET | 3844 | 57.95 |
| 03:50 ET | 2917 | 58.055 |
| 03:51 ET | 400 | 58.16 |
| 03:53 ET | 845 | 58.24 |
| 03:55 ET | 2099 | 58.2 |
| 03:57 ET | 1100 | 58.23 |
| 04:00 ET | 46836 | 58.29 |
Yesterday
Apogee Therapeutics to Participate in Upcoming November Investor Conferences, from 7:30AM ET on Monday Nov 04, 2024 by Dow Jones
7:30AM ET on Monday Nov 04, 2024 by Dow Jones
Oct 25, 2024
DJ Apogee Therapeutics Price Target Maintained With a $87.00/Share by Wedbush, from 11:19AM ET on Friday Oct 25, 2024 by Dow Jones
11:19AM ET on Friday Oct 25, 2024 by Dow Jones
Oct 24, 2024
Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, from 8:00AM ET on Thursday Oct 24, 2024 by Dow Jones
8:00AM ET on Thursday Oct 24, 2024 by Dow Jones
Oct 16, 2024
Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting, from 7:00AM ET on Wednesday Oct 16, 2024 by Dow Jones
7:00AM ET on Wednesday Oct 16, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Apogee Therapeutics Inc | 3.3B | -26.0x | --- |
Edgewise Therapeutics Inc | 3.2B | -23.4x | --- |
Xenon Pharmaceuticals Inc | 3.2B | -15.8x | --- |
Iovance Biotherapeutics Inc | 3.5B | -6.9x | --- |
Verona Pharma PLC | 3.1B | -24.7x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Company Information
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology (I&I) indications with high unmet need. Its advanced programs are APG777 and APG808, which are developed for the treatment of AD and COPD, respectively. APG777 is a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) targeting IL-13. APG808 is an SQ extended half-life mAb targeting IL-4Rα. Its earlier-stage programs, APG990 and APG222, utilize advanced antibody engineering to target OX40L and both IL-13 and OX40L, which are developed for the treatment of AD. APG990 is an SQ extended half-life mAb targeting OX40L for the treatment of AD. APG222 is one or more extended half-life SQ antibodies targeting both IL-13 and OX40L, which has the potential to improve outcomes in AD.
Contact Information
- Headquarters
- 221 Crescent St. Building 17, Suite 102bWALTHAM, MA, United States 02453
- Phone
- 650-394-5230
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Mark Mckenna
- Chief Executive Officer, Director
- Michael Henderson
- Chief Financial Officer
- Jane Henderson
- Chief Medical Officer
- Carl Dambkowski
- Independent Director
- Lisa Bollinger
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.3B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 58.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.25 |
Book Value | $7.86 |
P/E Ratio | -26.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
